SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Pascal Biosciences to Present at 2019 BIO International Convention
[May 29, 2019]

Pascal Biosciences to Present at 2019 BIO International Convention


Vancouver, BRITISH COLUMBIA and SEATTLE, May 29, 2019 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”), a drug discovery and development company, today announced the Company will present at the upcoming BIO International Convention taking place June 3-6 at the Pennsylvania Convention Center in Philadelphia. The BIO International Convention is the premier annual meeting for biotech and pharma, with more than 16,000 attendees gathering for partnering and networking opportunities.

Kevin Egan, VP Business Development at Pascal, will provide a corporate overview presentation highlighting the Company’s therapeutic pipeline on Tuesday, June 4 at 4:30 p.m. EDT in Theater 2, Level 200. Mr. Egan will describe recent advances in Pascal’s PAS-403 program for glioblastoma, which is advised by a world class group of neuro-oncologists. In addition, advances for PAS-393, a cannabinoid for enhancing immune checkpoint inhibitors for cancer, will also be presented. 

Members of the Pascal management team will be available for meetings during the BIO International Convention. To arrange a meeting with management, please contact bd@pascalbiosciences.com or visit the BIO One-one-One Partnering webpage to schedule a meeting directly.

About Pascal Biosciences Inc. 

Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer. Pascal is directed by a strong group of seasoned veteans of the biotech industry—these experts have started more than ten successful companies and also have discovered five approved therapeutics. The company’s leading portfolio includes cannabinoid-based therapeutics and targeted therapies. A small molecule therapeutic, PAS-403, is advancing into clinical trials for the treatment of glioblastoma, and the immuno-stimulatory cannabinoid PAS-393 will be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. For more information, visit www.pascalbiosciences.com.



Investors:
invest@pascalbiosciences.com

Media Contact:
Julie Rathbun
info@pascalbiosciences.com
Tel: 206-769-9219


DISCLAIMER
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Primary Logo


[ Back To TMCnet.com's Homepage ]









Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2019 Technology Marketing Corporation. All rights reserved | Privacy Policy